MIMS April 2013 prescribing update

New products

  • AndroForte 2 and AndroForte 5 (testosterone) is a transdermal system. It is indicated as testosterone replacement therapy in symptomatic testosterone deficient males, including confirmed primary hypogonadism, secondary hypogonadism and late-onset hypogonadism. Testosterone is contraindicated in men with known or suspected carcinoma of the prostate, breast, suspected androgen-dependent neoplasia, nephrotic syndrome or hypercalcaemia. AndroForte 2 and AndroForte 5 are available